Importance of gender in diffuse malignant peritoneal mesothelioma

Annals of Oncology

Volumn 23, Issue 6, 2012, Pages 1494-1498

  Cao, C ^a,b   Yan, T D ^a,b   Deraco, M ^c   Elias, D ^d   Glehen, O ^e   Levine, E A ^f   Moran, B J ^g   Morris, D L ^h   Chua, T C ^h   Piso, P ⁱ   Sugarbaker, P H ^j   Baratti, Dario ^c   Kusamura, Shigeki ^c   Gilly, Francois N ^e   Shen, Perry ^f   Mohamed, Faheez ^g  

^a The Baird Institute Australia   (Australia)

^b ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^c NATIONAL CANCER INSTITUTE   (Italy)

^d INSTITUT GUSTAVE ROUSSY   (France)

^e UNIVERSITÉ DE LYON   (France)

^f WAKE FOREST SCHOOL OF MEDICINE   (United States)

^g NORTH HAMPSHIRE HOSPITAL   (United Kingdom)

^h ST GEORGE HOSPITAL   (Australia)

ⁱ UNIVERSITY HOSPITAL REGENSBURG   (Germany)

^j WASHINGTON CANCER INSTITUTE   (United States)

more..

Author keywords

Cytoreductive surgery; HIPEC; Peritoneal mesothelioma; Peritonectomy; Sex

Indexed keywords

CISPLATIN; DOXORUBICIN;

ADULT; AGE DISTRIBUTION; ARTICLE; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CANCER REGISTRY; CANCER STAGING; CANCER SURGERY; COHORT ANALYSIS; CYTOREDUCTIVE SURGERY; DIFFUSE MALIGNANT PERITONEUM MESOTHELIOMA; FEMALE; HUMAN; HYPERTHERMIC INTRAPERITONEAL CHEMOTHERAPY; MAJOR CLINICAL STUDY; MALE; OPERATION DURATION; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PERIOPERATIVE COMPLICATION; PERIOPERATIVE PERIOD; PERITONEUM MESOTHELIOMA; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; SEX DIFFERENCE;

EID: 84861749414     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdr477     Document Type: Article

References (23)

1. Sridhar KS, Doria R, Raub WA Jr et al. New strategies are needed in diffuse malignant mesothelioma. Cancer 1992; 70: 2969-2979.
2. Spirtas R, Heineman EF, Bernstein L et al. Malignant mesothelioma: attributable risk of asbestos exposure. Occup Environ Med 1994; 51: 804-811.
3. Welch LS, Acherman YI, Haile E et al. Asbestos and peritoneal mesothelioma among college-educated men. Int J Occup Environ Health 2005; 11: 254-258.
4. Marinaccio A, Binazzi A, Cauzillo G et al. Analysis of latency time and its determinants in asbestos related malignant mesothelioma cases of the Italian register. Eur J Cancer 2007; 43: 2722-2728.
5. Robinson BW, Lake RA. Advances in malignant mesothelioma. N Engl J Med 2005; 353: 1591-1603.
6. Yan TD, Welch L, Black D, Sugarbaker PH. A systematic review on the efficacy of cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for diffuse malignancy peritoneal mesothelioma. Ann Oncol 2007; 18: 827-834.
7. Yan TD, Deraco M, Baratti D et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for malignant peritoneal mesothelioma: multiinstitutional experience. J Clin Oncol 2009; 27: 6237-6242.
8. Yan TD, Deraco M, Elias D et al. A novel tumor-node-metastasis (TNM) staging system of diffuse malignant peritoneal mesothelioma using outcome analysis of a multi-institutional database*. Cancer 2010; 18: 18.
9. Sugarbaker PH, Welch LS, Mohamed F, Glehen O. A review of peritoneal mesothelioma at the Washington Cancer Institute. Surg Oncol Clin N Am 2003; 12: 605-621.
10. Acherman YI, Welch LS, Bromley CM, Sugarbaker PH. Clinical presentation of peritoneal mesothelioma. Tumori 2003; 89: 269-273.
11. Yan TD, Brun EA, Cerruto CA et al. Prognostic indicators for patients undergoing cytoreductive surgery and perioperative intraperitoneal chemotherapy for diffuse malignant peritoneal mesothelioma. Ann Surg Oncol 2007; 14: 41-49.
12. Steele JP. Prognostic factors for mesothelioma. Hematol Oncol Clin North Am 2005; 19: 1041-1052.
13. Deraco M, Nonaka D, Baratti D et al. Prognostic analysis of clinicopathologic factors in 49 patients with diffuse malignant peritoneal mesothelioma treated with cytoreductive surgery and intraperitoneal hyperthermic perfusion. Ann Surg Oncol 2006; 13: 229-237.
14. Cerruto CA, Brun EA, Chang D, Sugarbaker PH. Prognostic significance of histomorphologic parameters in diffuse malignant peritoneal mesothelioma. Arch Pathol Lab Med 2006; 130: 1654-1661.
15. Feldman AL, Libutti SK, Pingpank JF et al. Analysis of factors associated with outcome in patients with malignant peritoneal mesothelioma undergoing surgical debulking and intraperitoneal chemotherapy. J Clin Oncol 2003; 21: 4560-4567.
16. Sugarbaker PH. Peritonectomy procedures. Ann Surg 1995; 221: 29-42.
17. Jacquet P, Sugarbaker PH. Clinical research methodologies in diagnosis and staging of patients with peritoneal carcinomatosis. Cancer Treat Res 1996; 82: 359-374.
18. Elias D, Gilly F, Boutitie F et al. Peritoneal colorectal carcinomatosis treated with surgery and perioperative intraperitoneal chemotherapy: retrospective analysis of 523 patients from a multicentric French study. J Clin Oncol 2010; 28: 63-68.
19. Pinton G, Brunelli E, Murer B et al. Estrogen receptor-beta affects the prognosis of human malignant mesothelioma. Cancer Res 2009; 69: 4598-4604.
20. Yan TD, Popa E, Brun EA et al. Sex difference in diffuse malignant peritoneal mesothelioma. Br J Surg 2006; 93: 1536-1542.
21. Wolf AS, Richards WG, Tilleman TR et al. Characteristics of malignant pleural mesothelioma in women. Ann Thorac Surg 2010; 90: 949-956.
22. Cocco P, Dosemeci M. Peritoneal cancer and occupational exposure to asbestos: results from the application of a job-exposure matrix. Am J Ind Med 1999; 35: 9-14.
23. Chua TC, Yao P, Akther J et al. Differential expression of Ki-67 and sex steroid hormone receptors between genders in peritoneal mesothelioma. Pathol Oncol Res 2009; 15: 671-678.